Aevi Genomic Medicine Inc
GNMX
GNMX was delisted on the 3rd of February, 2020.
44 hedge funds and large institutions have $27.2M invested in Aevi Genomic Medicine Inc in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 7 closing their positions.
87% more capital invested
Capital invested by funds: $14.6M → $27.2M (+$12.7M)
2% less funds holding
Funds holding: 45 → 44 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$2.15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$344K |
| 3 |
JP Morgan Chase
New York
|
+$186K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$164K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$94.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$74.9K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$50K |
| 3 |
Millennium Management
New York
|
-$34.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$30.2K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$25.3K |
GNMX Hedge Fund Activity: Q1 2018 in Review
44 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2018, worth a combined $27.2M — up 87% from $14.6M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GNMX and 6 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 5 added.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $2.15M. The largest seller was Renaissance Technologies, cutting an estimated $74.9K.
- 44 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2018, down from 45 in Q4 2017.
- Funds reported $27.2M of Aevi Genomic Medicine Inc stock for Q1 2018, up 87% quarter-over-quarter.
- 6 funds opened new Aevi Genomic Medicine Inc positions in Q1 2018 and 7 closed out, a net change of -1 holder.
- The largest Aevi Genomic Medicine Inc buyer in Q1 2018 was T. Rowe Price Associates, an estimated $2.15M added.
- The largest Aevi Genomic Medicine Inc seller in Q1 2018 was Renaissance Technologies, an estimated $74.9K sold.
Based on aggregated 13F filings for Q1 2018.